Camurus (OM:CAMX) just picked up a fresh regulatory win in Canada, as Health Canada granted a Notice of Compliance for Oczyesa XR for maintenance treatment of acromegaly in adults previously managed on somatostatin analogs.
At a share price of SEK635.0, Camurus has posted a 6.90% 1 month share price return and a 3.76% share price gain year to date, yet the 1 year total shareholder return is down 4.65% after a very large 5 year total shareholder return of 263.69%. This suggests momentum has cooled recently, even as fresh approvals like the Health Canada decision keep the long term story in focus.
Scan beyond Camurus and this acromegaly approval to see which other biopharma stocks with fresh catalysts and solid fundamentals are popping up in our curated list of 615 high quality undiscovered gems .
Camurus now trades at a clear discount to both analyst targets and an intrinsic value estimate, even after the Canada news bounce. Is that simply mispricing, or is the market pricing in real risk on the story ahead?
Most Popular Narrative: 5% Overvalued
On the narrative view, Camurus lines up with a fair value of SEK606.54 against a last close of SEK635, which puts the stock slightly above that reference point but still within a tight band that keeps both upside and downside firmly in play.
What I like about Camurus is the combination of an established pharmaceutical business, strong cash generation and a second potential growth engine that could scale through partnerships. The existing medicines help fund the journey. FluidCrystal provides the optionality.
See why 1 investors see Camurus as 5% overvalued .
Result: Fair Value of SEK606.54 (OVERVALUED)
Still, if FluidCrystal partnerships stall or key trials underperform, the Camurus premium to its SEK606.54 fair value could unwind faster than bullish narratives expect.
Find out about the key risks to this Camurus narrative .
Another View: SWS DCF Versus Camurus Narratives
That fair value of SEK606.54 casts Camurus as mildly overvalued on the narrative model, yet our DCF work tells a very different story. The SWS DCF model points to a future cash flow value of SEK1,310.61, which implies the shares trade at a steep discount. Which lens do you trust more when the signals conflict this sharply?
To see how that cash flow view is constructed and where the big sensitivities sit, Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out Camurus for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 188 high quality undervalued stocks . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If sentiment on Camurus feels split after this mix of fair value and DCF signals, consider moving quickly and stress test the upside yourself with the 3 key rewards .
Looking for more Camurus sized investment ideas?
Do not stop at Camurus. Use the Simply Wall St screener to surface fresh opportunities that match your style before everyone else is talking about them.
-
Target resilience first and hunt for companies with steadier risk profiles using our 223 resilient stocks with low risk scores .
-
Prioritise financial strength and seek out businesses with healthier balance sheets through the list of solid balance sheet and fundamentals (203 results) .
-
Chase value with discipline by scanning for quality stocks that trade below their estimated worth using the 188 high quality undervalued stocks .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include CAMX.ST .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
